Anti‐prothrombin IgG from patients with anti‐phospholipid antibodies inhibits the inactivation of factor Va by activated protein C
Summary Interference of anti‐phospholipid antibodies with the protein C pathway has been suggested to play a role in the development of thrombosis in the anti‐phospholipid syndrome. We studied the effect of IgG preparations containing anti‐prothrombin antibodies of 17 lupus anticoagulant‐positive pa...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2005-04, Vol.129 (2), p.240-247 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 247 |
|---|---|
| container_issue | 2 |
| container_start_page | 240 |
| container_title | British journal of haematology |
| container_volume | 129 |
| creator | Galli, Monica Willems, George M. Rosing, Jan Janssen, Rita M. Govers‐Riemslag, José W. P. Comfurius, Paul Barbui, Tiziano Zwaal, Robert F. A. Bevers, Edouard M. |
| description | Summary
Interference of anti‐phospholipid antibodies with the protein C pathway has been suggested to play a role in the development of thrombosis in the anti‐phospholipid syndrome. We studied the effect of IgG preparations containing anti‐prothrombin antibodies of 17 lupus anticoagulant‐positive patients and 12 controls on the inactivation of factor Va (FVa) by activated protein C (APC) in a system with purified coagulation factors. Test IgG was incubated with human prothrombin, phospholipid vesicles and CaCl2. Protein S, FVa and APC were added and the APC‐dependent loss of FVa activity was monitored over time. The residual amount of FVa remaining after 10 min was 14 ± 4% (mean ± SD) when 1·5 mg/ml normal IgG was present and ranged between 17% and 82% with 1·5 mg/ml patient IgG. Twelve patients IgG gave values of residual FVa >22% (i.e. 2 SD above the mean of controls), indicating that APC‐mediated inactivation of FVa was significantly inhibited. The inhibition was strictly dependent on the presence of prothrombin, proportional to the concentration of IgG and strongly diminished at a 20‐fold higher phospholipid concentration. Most, although not all, IgG containing anti‐prothrombin antibodies inhibit the APC‐catalysed FVa inactivation, which may contribute to the increased risk of thrombosis in patients with the anti‐phospholipid syndrome. |
| doi_str_mv | 10.1111/j.1365-2141.2005.05438.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67710932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67710932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4748-6086b5fadb9f901fafd98675d760dd8b4336b4f2fcc6c36ccb8e97969870fb23</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhi0EosvCX0AWEtwS7Dj-yIFDWUFbVIlLxdXyJ_EqGy92lnZvnDjzG_klON2ISpywZHnG87wzI70AQIxqXM7bbY0Jo1WDW1w3CNEa0ZaI-u4RWP0tPAYrhBCvMGrFGXiW8xYhTBDFT8EZpgITQZsV-Hk-TuH3j1_7FKc-xZ0OI7z6egF9ieFeTcGNU4a3YeqhWsg-5nKHsA_2_k9HG1yGYeyDDgWeelcSZabwvejjCKOHvqQxwS8K6iNcSs7CeaorEzfPwROvhuxeLO8a3Hz8cLO5rK4_X1xtzq8r0_JWVAwJpqlXVne-Q9grbzvBOLWcIWuFbglhuvWNN4YZwozRwnW8Y53gyOuGrMGbU9sy-NvB5UnuQjZuGNTo4iFLxjlGHZnBV_-A23hIY1lN4k5QzhssCiROkEkx5-S83KewU-koMZKzT3IrZzvkbIecfZL3Psm7In259D_onbMPwsWYArxeAJWNGnxSown5gWOMd6T4uQbvTtxtGNzxvxeQ7z9dzhH5A1alsig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198577218</pqid></control><display><type>article</type><title>Anti‐prothrombin IgG from patients with anti‐phospholipid antibodies inhibits the inactivation of factor Va by activated protein C</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><creator>Galli, Monica ; Willems, George M. ; Rosing, Jan ; Janssen, Rita M. ; Govers‐Riemslag, José W. P. ; Comfurius, Paul ; Barbui, Tiziano ; Zwaal, Robert F. A. ; Bevers, Edouard M.</creator><creatorcontrib>Galli, Monica ; Willems, George M. ; Rosing, Jan ; Janssen, Rita M. ; Govers‐Riemslag, José W. P. ; Comfurius, Paul ; Barbui, Tiziano ; Zwaal, Robert F. A. ; Bevers, Edouard M.</creatorcontrib><description>Summary
Interference of anti‐phospholipid antibodies with the protein C pathway has been suggested to play a role in the development of thrombosis in the anti‐phospholipid syndrome. We studied the effect of IgG preparations containing anti‐prothrombin antibodies of 17 lupus anticoagulant‐positive patients and 12 controls on the inactivation of factor Va (FVa) by activated protein C (APC) in a system with purified coagulation factors. Test IgG was incubated with human prothrombin, phospholipid vesicles and CaCl2. Protein S, FVa and APC were added and the APC‐dependent loss of FVa activity was monitored over time. The residual amount of FVa remaining after 10 min was 14 ± 4% (mean ± SD) when 1·5 mg/ml normal IgG was present and ranged between 17% and 82% with 1·5 mg/ml patient IgG. Twelve patients IgG gave values of residual FVa >22% (i.e. 2 SD above the mean of controls), indicating that APC‐mediated inactivation of FVa was significantly inhibited. The inhibition was strictly dependent on the presence of prothrombin, proportional to the concentration of IgG and strongly diminished at a 20‐fold higher phospholipid concentration. Most, although not all, IgG containing anti‐prothrombin antibodies inhibit the APC‐catalysed FVa inactivation, which may contribute to the increased risk of thrombosis in patients with the anti‐phospholipid syndrome.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/j.1365-2141.2005.05438.x</identifier><identifier>PMID: 15813852</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Antibodies, Antiphospholipid - immunology ; Antiphospholipid Syndrome - immunology ; anti‐phospholipid syndrome ; anti‐prothrombin antibodies ; Biological and medical sciences ; Case-Control Studies ; factor Va ; Factor Va - immunology ; Female ; Hematologic and hematopoietic diseases ; Hematology ; Humans ; Immunoglobulin G - blood ; Lupus Coagulation Inhibitor - immunology ; Lupus Erythematosus, Systemic - immunology ; Male ; Medical sciences ; Platelet diseases and coagulopathies ; protein C ; Protein C - immunology ; Prothrombin - immunology ; Stroke - immunology ; thrombosis ; Venous Thrombosis - immunology</subject><ispartof>British journal of haematology, 2005-04, Vol.129 (2), p.240-247</ispartof><rights>2005 INIST-CNRS</rights><rights>Copyright Blackwell Publishing Apr 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4748-6086b5fadb9f901fafd98675d760dd8b4336b4f2fcc6c36ccb8e97969870fb23</citedby><cites>FETCH-LOGICAL-c4748-6086b5fadb9f901fafd98675d760dd8b4336b4f2fcc6c36ccb8e97969870fb23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2141.2005.05438.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2141.2005.05438.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,1434,27929,27930,45579,45580,46414,46838</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16679301$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15813852$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Galli, Monica</creatorcontrib><creatorcontrib>Willems, George M.</creatorcontrib><creatorcontrib>Rosing, Jan</creatorcontrib><creatorcontrib>Janssen, Rita M.</creatorcontrib><creatorcontrib>Govers‐Riemslag, José W. P.</creatorcontrib><creatorcontrib>Comfurius, Paul</creatorcontrib><creatorcontrib>Barbui, Tiziano</creatorcontrib><creatorcontrib>Zwaal, Robert F. A.</creatorcontrib><creatorcontrib>Bevers, Edouard M.</creatorcontrib><title>Anti‐prothrombin IgG from patients with anti‐phospholipid antibodies inhibits the inactivation of factor Va by activated protein C</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
Interference of anti‐phospholipid antibodies with the protein C pathway has been suggested to play a role in the development of thrombosis in the anti‐phospholipid syndrome. We studied the effect of IgG preparations containing anti‐prothrombin antibodies of 17 lupus anticoagulant‐positive patients and 12 controls on the inactivation of factor Va (FVa) by activated protein C (APC) in a system with purified coagulation factors. Test IgG was incubated with human prothrombin, phospholipid vesicles and CaCl2. Protein S, FVa and APC were added and the APC‐dependent loss of FVa activity was monitored over time. The residual amount of FVa remaining after 10 min was 14 ± 4% (mean ± SD) when 1·5 mg/ml normal IgG was present and ranged between 17% and 82% with 1·5 mg/ml patient IgG. Twelve patients IgG gave values of residual FVa >22% (i.e. 2 SD above the mean of controls), indicating that APC‐mediated inactivation of FVa was significantly inhibited. The inhibition was strictly dependent on the presence of prothrombin, proportional to the concentration of IgG and strongly diminished at a 20‐fold higher phospholipid concentration. Most, although not all, IgG containing anti‐prothrombin antibodies inhibit the APC‐catalysed FVa inactivation, which may contribute to the increased risk of thrombosis in patients with the anti‐phospholipid syndrome.</description><subject>Antibodies, Antiphospholipid - immunology</subject><subject>Antiphospholipid Syndrome - immunology</subject><subject>anti‐phospholipid syndrome</subject><subject>anti‐prothrombin antibodies</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>factor Va</subject><subject>Factor Va - immunology</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunoglobulin G - blood</subject><subject>Lupus Coagulation Inhibitor - immunology</subject><subject>Lupus Erythematosus, Systemic - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Platelet diseases and coagulopathies</subject><subject>protein C</subject><subject>Protein C - immunology</subject><subject>Prothrombin - immunology</subject><subject>Stroke - immunology</subject><subject>thrombosis</subject><subject>Venous Thrombosis - immunology</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1v1DAQhi0EosvCX0AWEtwS7Dj-yIFDWUFbVIlLxdXyJ_EqGy92lnZvnDjzG_klON2ISpywZHnG87wzI70AQIxqXM7bbY0Jo1WDW1w3CNEa0ZaI-u4RWP0tPAYrhBCvMGrFGXiW8xYhTBDFT8EZpgITQZsV-Hk-TuH3j1_7FKc-xZ0OI7z6egF9ieFeTcGNU4a3YeqhWsg-5nKHsA_2_k9HG1yGYeyDDgWeelcSZabwvejjCKOHvqQxwS8K6iNcSs7CeaorEzfPwROvhuxeLO8a3Hz8cLO5rK4_X1xtzq8r0_JWVAwJpqlXVne-Q9grbzvBOLWcIWuFbglhuvWNN4YZwozRwnW8Y53gyOuGrMGbU9sy-NvB5UnuQjZuGNTo4iFLxjlGHZnBV_-A23hIY1lN4k5QzhssCiROkEkx5-S83KewU-koMZKzT3IrZzvkbIecfZL3Psm7In259D_onbMPwsWYArxeAJWNGnxSown5gWOMd6T4uQbvTtxtGNzxvxeQ7z9dzhH5A1alsig</recordid><startdate>200504</startdate><enddate>200504</enddate><creator>Galli, Monica</creator><creator>Willems, George M.</creator><creator>Rosing, Jan</creator><creator>Janssen, Rita M.</creator><creator>Govers‐Riemslag, José W. P.</creator><creator>Comfurius, Paul</creator><creator>Barbui, Tiziano</creator><creator>Zwaal, Robert F. A.</creator><creator>Bevers, Edouard M.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Blackwell Publishing Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200504</creationdate><title>Anti‐prothrombin IgG from patients with anti‐phospholipid antibodies inhibits the inactivation of factor Va by activated protein C</title><author>Galli, Monica ; Willems, George M. ; Rosing, Jan ; Janssen, Rita M. ; Govers‐Riemslag, José W. P. ; Comfurius, Paul ; Barbui, Tiziano ; Zwaal, Robert F. A. ; Bevers, Edouard M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4748-6086b5fadb9f901fafd98675d760dd8b4336b4f2fcc6c36ccb8e97969870fb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antibodies, Antiphospholipid - immunology</topic><topic>Antiphospholipid Syndrome - immunology</topic><topic>anti‐phospholipid syndrome</topic><topic>anti‐prothrombin antibodies</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>factor Va</topic><topic>Factor Va - immunology</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunoglobulin G - blood</topic><topic>Lupus Coagulation Inhibitor - immunology</topic><topic>Lupus Erythematosus, Systemic - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Platelet diseases and coagulopathies</topic><topic>protein C</topic><topic>Protein C - immunology</topic><topic>Prothrombin - immunology</topic><topic>Stroke - immunology</topic><topic>thrombosis</topic><topic>Venous Thrombosis - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Galli, Monica</creatorcontrib><creatorcontrib>Willems, George M.</creatorcontrib><creatorcontrib>Rosing, Jan</creatorcontrib><creatorcontrib>Janssen, Rita M.</creatorcontrib><creatorcontrib>Govers‐Riemslag, José W. P.</creatorcontrib><creatorcontrib>Comfurius, Paul</creatorcontrib><creatorcontrib>Barbui, Tiziano</creatorcontrib><creatorcontrib>Zwaal, Robert F. A.</creatorcontrib><creatorcontrib>Bevers, Edouard M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Galli, Monica</au><au>Willems, George M.</au><au>Rosing, Jan</au><au>Janssen, Rita M.</au><au>Govers‐Riemslag, José W. P.</au><au>Comfurius, Paul</au><au>Barbui, Tiziano</au><au>Zwaal, Robert F. A.</au><au>Bevers, Edouard M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti‐prothrombin IgG from patients with anti‐phospholipid antibodies inhibits the inactivation of factor Va by activated protein C</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2005-04</date><risdate>2005</risdate><volume>129</volume><issue>2</issue><spage>240</spage><epage>247</epage><pages>240-247</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>Summary
Interference of anti‐phospholipid antibodies with the protein C pathway has been suggested to play a role in the development of thrombosis in the anti‐phospholipid syndrome. We studied the effect of IgG preparations containing anti‐prothrombin antibodies of 17 lupus anticoagulant‐positive patients and 12 controls on the inactivation of factor Va (FVa) by activated protein C (APC) in a system with purified coagulation factors. Test IgG was incubated with human prothrombin, phospholipid vesicles and CaCl2. Protein S, FVa and APC were added and the APC‐dependent loss of FVa activity was monitored over time. The residual amount of FVa remaining after 10 min was 14 ± 4% (mean ± SD) when 1·5 mg/ml normal IgG was present and ranged between 17% and 82% with 1·5 mg/ml patient IgG. Twelve patients IgG gave values of residual FVa >22% (i.e. 2 SD above the mean of controls), indicating that APC‐mediated inactivation of FVa was significantly inhibited. The inhibition was strictly dependent on the presence of prothrombin, proportional to the concentration of IgG and strongly diminished at a 20‐fold higher phospholipid concentration. Most, although not all, IgG containing anti‐prothrombin antibodies inhibit the APC‐catalysed FVa inactivation, which may contribute to the increased risk of thrombosis in patients with the anti‐phospholipid syndrome.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>15813852</pmid><doi>10.1111/j.1365-2141.2005.05438.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2005-04, Vol.129 (2), p.240-247 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67710932 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; Wiley Online Library (Open Access Collection) |
| subjects | Antibodies, Antiphospholipid - immunology Antiphospholipid Syndrome - immunology anti‐phospholipid syndrome anti‐prothrombin antibodies Biological and medical sciences Case-Control Studies factor Va Factor Va - immunology Female Hematologic and hematopoietic diseases Hematology Humans Immunoglobulin G - blood Lupus Coagulation Inhibitor - immunology Lupus Erythematosus, Systemic - immunology Male Medical sciences Platelet diseases and coagulopathies protein C Protein C - immunology Prothrombin - immunology Stroke - immunology thrombosis Venous Thrombosis - immunology |
| title | Anti‐prothrombin IgG from patients with anti‐phospholipid antibodies inhibits the inactivation of factor Va by activated protein C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T14%3A24%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti%E2%80%90prothrombin%20IgG%20from%20patients%20with%20anti%E2%80%90phospholipid%20antibodies%20inhibits%20the%20inactivation%20of%20factor%20Va%20by%20activated%20protein%20C&rft.jtitle=British%20journal%20of%20haematology&rft.au=Galli,%20Monica&rft.date=2005-04&rft.volume=129&rft.issue=2&rft.spage=240&rft.epage=247&rft.pages=240-247&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1111/j.1365-2141.2005.05438.x&rft_dat=%3Cproquest_cross%3E67710932%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198577218&rft_id=info:pmid/15813852&rfr_iscdi=true |